Stifel downgraded RxSight (RXST) to Hold from Buy with a price target of $40, down from $65. The firm’s latest deep-dive survey of surgeons leads to believe that the risk from U.S. premium IOL – intraocular lens – competition may be more material than investors appreciate, with JNJ‘s (JNJ) new Tecnis Odyssey lens “jumping off the page” in its findings and with Alcon’s (ALC) PanOptix Pro around the corner, the analyst tells investors in a research note. Stifel adds that its longitudinal analysis shows the respondents’ 2025 LAL – light adjustable lenses – volume expectations are moderately weakening, giving the firm pause around the intermediate-term LAL path ahead.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RXST:
- Needham ups Alcon target, adds to Conviction List
- RxSight downgraded to Equal Weight from Overweight at Wells Fargo
- RxSight initiated with a Buy at UBS
- RxSight, Inc. Reports Strong Q3 Financial Results
- Closing Bell Movers: Toast gains 19% afterhours after earnings beat
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
